Abstract
This chapter is about assessment of ROP neonates. The correct assessment of plus disease and of zone I or zone II is crucial for determining the correct timing and choice of treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Austeng D, Källen KB, Ewald UW, Wallin A, Holmström GE. Treatment for retinopathy of prematurity in infants born before 27 weeks of gestation in Sweden. Br J Ophthalmol. 2010;94(9):1136–9.
Holmström G, Tornqvist K, Al-Hawasi A, Nilsson Å, Wallin A, Hellström A. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol. 2018 Mar;96(2):142–8.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Spandau, U., Kim, S.J. (2019). Assessment of ROP Neonates. In: Pediatric Retinal Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13701-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-13701-4_9
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13700-7
Online ISBN: 978-3-030-13701-4
eBook Packages: MedicineMedicine (R0)